Show simple item record

dc.contributorNot Applicableen_US
dc.contributor.authorLACKNER, JEFFREY M Principal Investigatoren_US
dc.date30-Apr-15en_US
dc.date2010en_US
dc.date.accessioned2011-04-18T21:08:01Zen_US
dc.date.accessioned2011-04-19T18:30:33Z
dc.date.available15-May-08en_US
dc.date.available2011-04-18T21:08:01Zen_US
dc.date.available2011-04-19T18:30:33Z
dc.date.issued2011-04-18T21:08:01Zen_US
dc.identifier7846740en_US
dc.identifier5U01DK077738-03en_US
dc.identifier77738en_US
dc.identifier.urihttp://hdl.handle.net/10477/965
dc.descriptionAbdominal Pain;Acute;Address;Aftercare;Area;Attention;base;Behavior Therapy;Behavioral;Belief;Characteristics;Chronic;Client satisfaction;Climacteric;Clinic Visits;Clinical;Clinical effectiveness;Clinical Trials;Cognitive;Cognitive Therapy;Control Locus;cost;cost effectiveness;Coupled;Data;Development;Diagnosis;Distress;Economic Burden;economic cost;Economics;effective therapy;Ensure;Etiology;Expectancy;Facilities and Administrative Costs;Feces;follow-up;Functional disorder;Funding;Gastrointestinal Diseases;Generations;Goals;Healthcare;Healthcare Systems;Human;improved;Intestines;Irritable Bowel Syndrome;Mediating;Mediator of activation protein;Medical;Motivation;Multi-Institutional Clinical Trial;Multicenter Trials;novel;Outcome;Patient Care;Patients;Phase;Pilot Projects;Placebos;Protocols documentation;psychologic;psychological distress;psychosocial;Quality of life;Recruitment Activity;Relative (related person);Research;Research Infrastructure;response;Rome;Sampling;Self Efficacy;Self-Administered;Severities;Site;Subgroup;success;Symptoms;System;Testing;theories;Therapeutic;To specify;Translating;treatment effect;Treatment outcome;treatment program;treatment response;treatment site;Validation;en_US
dc.descriptionAmount: $ 1240406en_US
dc.description.abstractDESCRIPTION (provided by applicant): Irritable bowel syndrome (IBS) is a chronic, prevalent, often disabling, GI disorder for which there is no reliable and satisfactory medical option for its full range of symptoms (abdominal pain, bowel dysfunction). An accumulating body of evidence indicates that a specific psychosocial treatment called cognitive behavioral therapy (CBT) is associated with significant reductions in IBS symptoms and related difficulties. Despite its apparent efficacy, CBT's clinical effectiveness (i.e., its generalizability, feasibility, cost effectiveness) has not been adequately established due partly to its duration, cost, and limited accessibility. As the 'second generation' of IBS treatments undergo development and validation, it has become increasingly clear that efficacy demonstration is a necessary but not sufficient condition of treatment viability. In a pilot study funded under NIDDK's R03 mechanism, we addressed these problems by developing a briefer, largely self administered version of CBT that requires only 4, I hr clinic visits. Our RCT data showed that a 10 session version of CBT can be translated into a 4 session version without compromising patient acceptability or short term efficacy. It is unclear whether treatment effects are maintained long term (out to 12 months), due to theoretical change mechanisms (vs. nonspecific factors common across different forms of therapy), are more pronounced among specific subgroups of patients, or, generalize to a large sample of Rome III diagnosed patients treated by different investigative sites. We seek to address these questions by conducting a larger, more definitive, multisite RCT that will recruit from 3 treatment sites 480 patients with moderate to severe IBS and assess their acute and long term response to brief (4 session) CBT, extended (10 session) CBT, or a credible attention placebo. We will use the first year to develop a clinical infrastructrue [sic] to ensure the success and integrity of the proposed trial. In the short term, a successful trial will lend empirical validation to a self administered version of CBT that retains the efficacy of standard CBT but is more transportable, accessible to patients outside of research protocols, and less costly to deliver. In the long term, we hope to show that a self guided behavioral treatment program is an effective and efficient treatment delivery system that can enhance the quality of patient care, improve clinical outcomes, and decrease the economic and personal costs of one of the most prevalent and intractable GI disorders. The primary goal of the proposed trial is to assess the short- and long-term efficacy of cognitive behavior therapy (CBT) for irritable bowel syndrome using two treatment delivery systems (self administered, therapist administered). Secondary aims seek to specify the conditions under which CBT may (or may not) achieve its effects (moderator questions), why and how these effects are achieved (mediator questions) and at what economic cost. Long term project goals are to develop an effective self-administered behavioral treatment program that can enhance the quality of patient care, improve clinical outcomes, and decrease the economic and personal costs of one of the most prevalent and intractable GI disorders.en_US
dc.titleSELF-ADMINISTERED CBT FOR IBS: A MULTICENTER TRIALen_US
dc.typeNIH Grant Awarden_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record